META vs MRDN

META exhibits exceptional fundamental health with a Piotroski F-Score of 8/9, indicating strong financial strength across profitability, leverage, and operating efficiency. While the current price of $612.42 trades at a premium to the Graham Number ($213.17) and the growth-based Intrinsic Value ($542.14), the PEG ratio of 0.94 suggests the stock is undervalued relative to its high growth rate. Strong revenue growth (23.8%) and a low forward P/E (17.03) outweigh the bearish technical trend and insider selling. The company's dominant market position and consistent earnings beats support a bullish long-term outlook.

MRDN exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a critical liquidity position with a current ratio of 0.59. Despite a decent gross margin, the company suffers from massive negative ROE (-116.96%) and catastrophic earnings misses, including a recent surprise of -19,450%. There is a stark divergence between the bearish fundamental/technical data and the 'strong_buy' analyst consensus, which is not supported by the current cash flow or profitability profile. The stock is in a clear long-term downtrend, losing over 70% of its value in the last year.